en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
2/2021
vol. 96
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Opis przypadku

Characteristics of patients with blastemal-type Wilms’ tumour

Weronika Hajzler
1
,
Joanna Kopera
2
,
Klaudia Kosek
2
,
Dorota Mazur
2
,
Iwona Rurańska
3
,
Tomasz Szczepański
3
,
Aneta Pobudejska-Pieniążek
3

  1. Doctoral School, Department of Pediatric Hematology and Oncology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
  2. Students’ Scientific Association, Department of Pediatric Hematology and Oncology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
  3. Department of Pediatric Hematology and Oncology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
Pediatr Pol 2021; 96 (2): 134–138
Data publikacji online: 2021/07/01
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Wilms’ tumour (nephroblastoma) is the most common malignant tumour of kidney in children and one of the 2 most common solid tumours located outside of the central nervous system. Nephroblastoma has a very good prognosis, but some histological types like blastemal-type require qualification to a high-risk group and intensification of treatment. We present the cases of 3 children diagnosed with nephroblastoma, blastemal-type. The first girl’s treatment was unsuccessful, as there were 4 cancer recurrences. The second girl had primarily metachronous form of nephroblastoma, but during recurrence the blastemal-type was diagnosed. Despite intensive treatment, it ended with failure. The third girl had a tumour in the left kidney, which was transformed from the bilateral nephroblastomatosis. She remains in remission; the therapy ended on February 2018.